Antimicrobial resistance is projected to kill up to 10 million people a year by 2050. We won’t let this happen.
TAXIS Pharmaceuticals is developing therapies to combat antimicrobial resistance addressing the root cause of the issue, targeting the very foundation of bacterial survival. Our approach goes beyond traditional methods – we’re dismantling the cellular infrastructure, breaking down barriers, and disrupting the mechanisms that fuel antimicrobial resistance.
At TAXIS Pharmaceuticals, we envision a world where antimicrobial resistance is a thing of the past.
Our Investigational Therapeutics
Read our latest news and insights
Joe DePinto, MBA and Frank Carlo Pasqualone, MBA Named to Board of Directors
TAXIS Pharmaceuticals has named two industry professionals with extensive biopharma experience, Joeseph DePinto, MBA, and Frank Carlo Pasqualone, MBA, to its Board of Directors.
Hospital-Acquired Pneumonia: Rethinking Treatment in the Face of Antibiotic Resistance
Hospital-acquired pneumonia (HAP) stands as one of the most significant challenges in patient care, representing a leading cause of morbidity among hospitalized patients. This formidable infection not only contributes to extended hospital stays but also leads to increased healthcare costs and a greater burden on healthcare systems. Companies like TAXIS Pharmaceuticals have the potential to transform outcomes for patients battling this condition.
Tackling Antimicrobial Resistance With Precision Targeting in Drug Discovery Online
A conversation with Gregory G. Mario and Ajit K. Parhi, Ph.D., TAXIS Pharmaceuticals originally published in Drug Discovery Online.